AGC
XLRN

Alden Global Capital’s Acceleron Pharma XLRN Stock Holding History

Alden Global Capital’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-33,700
Closed -$860K – 11
2016
Q4 		$860K Buy
+33,700
New +$1.07M 0.29% 11

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Alden Global Capital's XLRN Position: Q1 2017 in Review

Alden Global Capital sold out of Acceleron Pharma (XLRN) in Q1 2017, closing a stake of 33,700 shares — an estimated $860K sold.

Alden Global Capital first reported a position in XLRN in Q4 2016 and held it in 1 quarter. The position peaked at $860K in Q4 2016. 136 funds tracked by Wall St. Rank hold XLRN as of Q1 2017.

  • Alden Global Capital reported no remaining Acceleron Pharma position as of Q1 2017 after selling out during the quarter.
  • Alden Global Capital sold 33,700 Acceleron Pharma shares in Q1 2017, an estimated $860K.
  • Alden Global Capital first reported a position in Acceleron Pharma in Q4 2016 and held it in 1 quarter.
  • Alden Global Capital's Acceleron Pharma position peaked at $860K in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2017.

Based on Alden Global Capital's 13F filing for Q1 2017, filed 11 May 2017.